F-star, Takeda Agree to Antibody Development Collaboration
Partnership to focus on developing immunotherapies for patients with cancer.
F-star Therapeutics, a biopharmaceutical company, has announced a strategic partnership with Takeda. As per the deal, the organizations will jointly research and develop novel Fcab ™ domains against undisclosed immuno-oncology targets for cancer patients, with Takeda receiving exclusive royalty-bearing license to research, develop, and commercialize antibodies incorporating Fcab domains. F-star will retain the rights on other domains.
“We are delighted to expand our relationship with Takeda who shares our vision of developing pioneering multi-specific immunotherapies so more people with cancer can live longer with improved lives,” said Neil Brewis, PhD, chief scientific officer, F-star Therapeutics. “This strategic collaboration leverages the capabilities of both companies by combining F-star’s clinically validated Fcab™ and mAb² ™ platforms with Takeda’s unique understanding of the immune system and its ability to progress drugs to the clinic.”
Reference: F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies. GlobeNewswire. July 5, 2023. Accessed July 6, 2023. https://www.globenewswire.com/news-release/2023/07/05/2699446/0/en/F-star-an-invoX-Company-Announces-Strategic-Collaboration-and-Licence-Agreement-with-Takeda-to-Discover-and-Develop-Next-Generation-Multi-Specific-Antibodies.html
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
